Company Name: | Arena Pharmaceuticals Inc | | Ticker Symbol: | ARNA | CIK Number: | 0001080709 | WWW Address: | http://www.arenapharm.com |
CEO: | Mr. Amit D. Munshi | No. of Employees: | 106 |
Common Issue Type: | CS | Business Description: | Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas like cardiovascular & metabolic diseases.
|
| | Industry Information: | DRUGS - Biotechnology [more like this] |
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | 39.15 | -0.54 | 39.13 | 39.16 | 39.95 | 39.82 | 38.82 | 610399 |
Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
1,925.3 | 49.2 | 0.00 | -2.77 | 0.00 | 0.0 | 0.0 | 45.85 - 1.13 |
| KEY FIGURES (Latest Twelve Months - LTM) | Yesterday's Close | 39.70 | $ | PE Ratio - LTM | 0.0 | |
Market Capitalisation | 1,925.3 | mil |
Latest Shares Outstanding | 49.2 | mil |
Earnings pS (EPS) | -2.77 | $ |
Dividend pS (DPS) | 0.00 | ¢ |
Dividend Yield | 0.0 | % |
Dividend Payout Ratio | | % |
Revenue per Employee | 134,195 | $ |
Effective Tax Rate | 0.0 | % |
Float | 24.7 | mil |
Float as % of Shares Outstanding | 1.0 | % |
Foreign Sales | | mil |
Domestic Sales | | mil |
Selling, General & Adm/tive (SG&A) as % of Revenue | 1.40 | % |
Research & Devlopment (R&D) as % of Revenue | 3.30 | % |
Gross Profit Margin | 0.0 | % |
EBITDA Margin | -400.5 | % |
Pre-Tax Profit Margin | 0.0 | % |
Assets Turnover | 8.4 | % |
Return on Assets (ROA) | -36.0 | % |
Return on Equity (ROE) | -74.0 | % |
Return on Capital Invested (ROCI) | -45.9 | % |
Current Ratio | 3.9 | |
Leverage Ratio (Assets/Equity) | 1.6 | |
Interest Cover | -14.7 | |
Total Debt/Equity (Gearing Ratio) | 0.30 | |
LT Debt/Total Capital | 22.0 | % |
Working Capital pS | 4.25 | $ |
Cash pS | 0.00 | $ |
Book-Value pS | 4.21 | $ |
Tangible Book-Value pS | 4.21 | $ |
Cash Flow pS | -2.02 | $ |
Free Cash Flow pS | -2.02 | $ |
 |
KEY FIGURES (LTM): Price info |
Price/Book Ratio | 9.43 | |
Price/Tangible Book Ratio | 0.00 | |
Price/Cash Flow | | |
Price/Free Cash Flow | | |
P/E as % of Industry Group | 0.0 | % |
P/E as % of Sector Segment | 0.0 | % |
| | Balance Sheet (at a glance) in Millions |
| | | DIVIDEND INFO | Type of Payment | - |
Dividend Rate | 0.00 |
Current Dividend Yield | 0.0 |
5-Y Average Dividend Yield | 0.0 |
Payout Ratio | 0.0 |
5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | Share price performance previous 3 years |
| 
|  | Share price performance intraday |
| 
| | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
1 Week | - | - | - | 10.0 | 9 | 1,017,771 | 5,570,865 |
4 Weeks | 42.89 | 33.21 | 41.90 | -6.3 | -9 | 1,318,712 | 26,374,256 |
13 Weeks | 45.85 | 30.00 | 35.59 | 10.3 | 15 | 1,215,752 | 77,808,135 |
26 Weeks | 45.85 | 24.33 | 27.29 | 43.9 | 40 | 836,746 | 104,593,269 |
52 Weeks | 45.85 | 1.13 | 1.30 | 2920.8 | 2907 | 1,021,654 | 257,456,841 |
YTD | 45.85 | 30.00 | - | 8.5 | 9 | 1,139,871 | 86,630,209 |
Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 37.89 | 36.82 | 38.82 | 33.56 | 30.63 | 0.00 | 0.00 |
| | GROWTH RATES | 5-Year Growh | R² of 5-Year Growth | 3-Year Growth |
Revenue | -0.05 | 0.0 | -0.17 |
Income | | 0.0 | |
Dividend | | 0.0 | |
Capital Spending | | NA | |
R&D | -22.62 | NA | -18.37 |
Normalized Inc. | 0.00 | NA | 0.00 |
| | CHANGES | YTD vs. Last YTD | Curr Qtr vs. Qtr 1-Yr ago | Annual vs. Last Annual |
Revenue % | 8.4 | 8.4 | 116.9 |
Earnings % | 0.0 | 0.0 | 0.0 |
EPS % | 0.0 | 0.0 | 0.0 |
EPS $ | 0.09 | 0.09 | 0.35 |
| | SOLVENCY RATIOS | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
Net Working Capital Ratio | 61.59 |
Current Ratio | 3.9 |
Quick Ratio (Acid Test) | 3.6 |
Liquidity Ratio (Cash) | 5.61 |
Receivables Turnover | 1.9 |
Average Collection Period | 189 |
Working Capital/Equity | 100.9 |
Working Capital pS | 5.30 |
Cash-Flow pS | -2.02 |
Free Cash-Flow pS | -2.02 |
FINANCIAL STRUCTURE RATIOS |
Altman's Z-Score Ratio | 8.45 |
Financial Leverage Ratio (Assets/Equity) | 0.3 |
Debt Ratio | 18.2 |
Total Debt/Equity (Gearing Ratio) | 0.30 |
LT Debt/Equity | 0.28 |
LT Debt/Capital Invested | 28.9 |
LT Debt/Total Liabilities | 0.0 |
Interest Cover | -14.7 |
Interest/Capital Invested | 2.29 |
| | VALUATION RATIOS | MULTIPLES |
PQ Ratio | 0.00 |
Tobin's Q Ratio | 5.75 |
Current P/E Ratio - LTM | 0.00 |
Enterprise Value (EV)/EBITDA | -19.64 |
Enterprise Value (EV)/Free Cash Flow | -23.48 |
Dividend Yield | 0.0 |
Price/Tangible Book Ratio - LTM | 0.00 |
Price/Book Ratio - LTM | 9.43 |
Price/Cash Flow Ratio | |
Price/Free Cash Flow Ratio - LTM | |
Price/Sales Ratio | 0.00 |
P/E Ratio (1 month ago) - LTM | 0.0 |
P/E Ratio (26 weeks ago) - LTM | 0.0 |
P/E Ratio (52 weeks ago) - LTM | 0.0 |
5-Y High P/E Ratio | 0.0 |
5-Y Low P/E Ratio | 0.0 |
5-Y Average P/E Ratio | 0.0 |
Current P/E Ratio as % of 5-Y Average P/E | |
P/E as % of Industry Group | 0.0 |
P/E as % of Sector Segment | 0.0 |
Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
PER SHARE FIGURES |
LT Debt pS | 0.00 |
Current Liabilities pS | 2.93 |
Tangible Book Value pS - LTM | 4.21 |
Book Value pS - LTM | 4.21 |
Capital Invested pS | 4.21 |
Cash pS - LTM | 0.00 |
Cash Flow pS - LTM | -2.02 |
Free Cash Flow pS - LTM | -2.02 |
Earnings pS (EPS) | -2.77 |
| | OPERATING RATIOS | PROFITABILITY RATIOS |
Free Cash Flow Margin | -312.86 |
Free Cash Flow Margin 5YEAR AVG | -173.72 |
Net Profit Margin | -3.9 |
Net Profit Margin - 5YEAR AVRG. | -1.8 |
Equity Productivity | 0.10 |
Return on Equity (ROE) | -0.7 |
Return on Equity (ROE) - 5YEAR AVRG. | -0.9 |
Capital Invested Productivity | 0.10 |
Return on Capital Invested (ROCI) | -0.4 |
Return on Capital Invested (ROCI) - 5YEAR AVRG. | -0.4 |
Assets Productivity | 0.10 |
Return on Assets (ROA) | -0.4 |
Return on Assets (ROA) - 5YEAR AVRG. | -0.2 |
Gross Profit Margin | 0.0 |
Gross Profit Margin - 5YEAR AVRG. | |
EBITDA Margin - LTM | -400.5 |
EBIT Margin - LTM | -420.6 |
Pre-Tax Profit Margin | -1.9 |
Pre-Tax Profit Margin - 5YEAR AVRG. | -1.9 |
Effective Tax Rate | 0.0 |
Effective Tax Rate - 5YEAR AVRG. | 0.0 |
EFFICIENCY RATIOS |
Cash Conversion Cycle | 74,669 |
Revenue per Employee | 134,195 |
Net Income per Employee | |
Average Collection Period | 74,669 |
Receivables Turnover | 1.9 |
Day's Inventory Turnover Ratio | |
Inventory Turnover | 0.0 |
Inventory/Sales | 0.0 |
Accounts Payble/Sales | 7.49 |
Assets/Revenue | 10.00 |
Net Working Capital Turnover | 0.10 |
Fixed Assets Turnover | 0.37 |
Total Assets Turnover | 0.1 |
Revenue per $ Cash | 0.13 |
Revenue per $ Plant | 0.71 |
Revenue per $ Common Equity | 0.10 |
Revenue per $ Capital Invested | 0.10 |
Selling, General & Adm/tive (SG&A) as % of Revenue | 142.2 |
SG&A Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
Research & Devlopment (R&D) as % of Revenue | 332.7 |
R&D Expense as % of Revenue - 5YEAR AVRG. | 332.7 |
|
|  





| |  |  | | |